HK1079430A1 - Liquid preparation comprising oligopeptides and etherified cyclodextrin - Google Patents
Liquid preparation comprising oligopeptides and etherified cyclodextrinInfo
- Publication number
- HK1079430A1 HK1079430A1 HK05111395A HK05111395A HK1079430A1 HK 1079430 A1 HK1079430 A1 HK 1079430A1 HK 05111395 A HK05111395 A HK 05111395A HK 05111395 A HK05111395 A HK 05111395A HK 1079430 A1 HK1079430 A1 HK 1079430A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- oligopeptides
- liquid preparation
- etherified cyclodextrin
- etherified
- cyclodextrin
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Nanotechnology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Medical Informatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10228049A DE10228049A1 (de) | 2002-06-24 | 2002-06-24 | Flüssige Zubereitung enthaltend Oligopeptide |
| PCT/EP2003/005224 WO2004000344A1 (de) | 2002-06-24 | 2003-05-19 | Flüssige zubereitung enthaltend oligopeptide und verethertes cyclodextrin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1079430A1 true HK1079430A1 (en) | 2006-04-07 |
Family
ID=29723395
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK05111395A HK1079430A1 (en) | 2002-06-24 | 2005-12-12 | Liquid preparation comprising oligopeptides and etherified cyclodextrin |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US7262165B2 (pt) |
| EP (1) | EP1515740B1 (pt) |
| JP (1) | JP5052750B2 (pt) |
| KR (1) | KR101024511B1 (pt) |
| CN (1) | CN100368013C (pt) |
| AR (1) | AR040444A1 (pt) |
| AT (1) | ATE337013T1 (pt) |
| AU (1) | AU2003240268B2 (pt) |
| BR (1) | BR0312157A (pt) |
| CA (1) | CA2490735C (pt) |
| CY (1) | CY1105706T1 (pt) |
| DE (2) | DE10228049A1 (pt) |
| DK (1) | DK1515740T3 (pt) |
| ES (1) | ES2270042T3 (pt) |
| HK (1) | HK1079430A1 (pt) |
| MX (1) | MXPA04012426A (pt) |
| MY (1) | MY135548A (pt) |
| PL (1) | PL205972B1 (pt) |
| PT (1) | PT1515740E (pt) |
| RU (1) | RU2322254C2 (pt) |
| WO (1) | WO2004000344A1 (pt) |
| ZA (1) | ZA200500585B (pt) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100834232B1 (ko) | 2004-01-30 | 2008-05-30 | 화이자 프로덕츠 인크. | 액체 투여형용 베타-시클로덱스트린을 사용하는 다수회투여 제형을 얻기 위한 항균 방부제 |
| DE102004011512B4 (de) | 2004-03-08 | 2022-01-13 | Boehringer Ingelheim Vetmedica Gmbh | Pharmazeutische Zubereitung enthaltend Pimobendan |
| US8980894B2 (en) | 2004-03-25 | 2015-03-17 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure |
| EP1579862A1 (en) | 2004-03-25 | 2005-09-28 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure |
| JP5272126B2 (ja) * | 2006-06-29 | 2013-08-28 | リンク・ジェノミクス株式会社 | 抗生物質の注射剤及びその投与液 |
| EP1920785A1 (en) * | 2006-11-07 | 2008-05-14 | Boehringer Ingelheim Vetmedica Gmbh | Liquid preparation comprising a complex of pimobendan and cyclodextrin |
| PL2101805T3 (pl) * | 2007-01-18 | 2013-04-30 | Merck Patent Gmbh | Ligandy integryn do stosowania w leczeniu nowotworów |
| EP2247449B1 (en) * | 2008-03-01 | 2018-10-31 | Hewlett-Packard Development Company, L.P. | Detecting colorants within carrier liquid |
| CN102281903B (zh) * | 2008-11-17 | 2013-11-13 | 弗·哈夫曼-拉罗切有限公司 | 降低大分子在生理条件下聚集的方法和配方 |
| PT2370070E (pt) | 2008-11-25 | 2013-11-18 | Boehringer Ingelheim Vetmed | Utilização de pimobendano para o tratamento da cardiomiopatia hipertrófica felina |
| MX2012006450A (es) * | 2009-12-10 | 2012-06-28 | Merck Patent Gmbh | Composicion farmaceutica que comprende oligopeptidos. |
| ES2924478T3 (es) | 2012-03-15 | 2022-10-07 | Boehringer Ingelheim Vetmedica Gmbh | Formulación de comprimidos farmacéuticos para el sector médico veterinario, método de producción y uso de los mismos |
| CN113181110A (zh) | 2013-07-19 | 2021-07-30 | 勃林格殷格翰动物保健有限公司 | 含有防腐的醚化的环糊精衍生物的液体水性药物组合物 |
| WO2015082389A1 (en) | 2013-12-04 | 2015-06-11 | Boehringer Ingelheim Vetmedica Gmbh | Improved pharmaceutical compositions of pimobendan |
| KR20180098625A (ko) | 2015-12-30 | 2018-09-04 | 제넨테크, 인크. | 분해가 감소된 폴리소르베이트를 갖는 제형 |
| US10537570B2 (en) | 2016-04-06 | 2020-01-21 | Boehringer Ingelheim Vetmedica Gmbh | Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease |
| US10975121B2 (en) | 2017-06-24 | 2021-04-13 | Cytogel Pharma, Llc | Analgesic mu-opioid receptor binding peptide pharmaceutical formulations and uses thereof |
| ES2969958T3 (es) * | 2017-11-30 | 2024-05-23 | Cytogel Pharma Llc | Formulaciones farmacéuticas analgésicas novedosas y usos de las mismas |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3346123A1 (de) * | 1983-12-21 | 1985-06-27 | Janssen Pharmaceutica, N.V., Beerse | Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung |
| GB9001987D0 (en) * | 1990-01-29 | 1990-03-28 | Janssen Pharmaceutica Nv | Improved cyclodextrin based erythropietin formulation |
| JP3934705B2 (ja) * | 1995-05-26 | 2007-06-20 | ノバルティス ファーマ株式会社 | サイクロデキストリン組成物 |
| DE19534177A1 (de) * | 1995-09-15 | 1997-03-20 | Merck Patent Gmbh | Cyclische Adhäsionsinhibitoren |
| MXPA01010247A (es) | 1999-04-15 | 2002-03-27 | Lilly Co Eli | Composiciones antifungosas de pseudomicina y metodos para su uso. |
-
2002
- 2002-06-24 DE DE10228049A patent/DE10228049A1/de not_active Withdrawn
-
2003
- 2003-05-19 MX MXPA04012426A patent/MXPA04012426A/es active IP Right Grant
- 2003-05-19 EP EP03732406A patent/EP1515740B1/de not_active Expired - Lifetime
- 2003-05-19 US US10/518,924 patent/US7262165B2/en not_active Expired - Fee Related
- 2003-05-19 KR KR1020047020993A patent/KR101024511B1/ko not_active IP Right Cessation
- 2003-05-19 RU RU2005101746/15A patent/RU2322254C2/ru not_active IP Right Cessation
- 2003-05-19 PT PT03732406T patent/PT1515740E/pt unknown
- 2003-05-19 CN CNB038149273A patent/CN100368013C/zh not_active Expired - Fee Related
- 2003-05-19 DK DK03732406T patent/DK1515740T3/da active
- 2003-05-19 ES ES03732406T patent/ES2270042T3/es not_active Expired - Lifetime
- 2003-05-19 DE DE50304763T patent/DE50304763D1/de not_active Expired - Lifetime
- 2003-05-19 AT AT03732406T patent/ATE337013T1/de active
- 2003-05-19 BR BR0312157-7A patent/BR0312157A/pt not_active IP Right Cessation
- 2003-05-19 CA CA2490735A patent/CA2490735C/en not_active Expired - Fee Related
- 2003-05-19 AU AU2003240268A patent/AU2003240268B2/en not_active Ceased
- 2003-05-19 WO PCT/EP2003/005224 patent/WO2004000344A1/de active IP Right Grant
- 2003-05-19 PL PL372192A patent/PL205972B1/pl not_active IP Right Cessation
- 2003-05-19 JP JP2004514642A patent/JP5052750B2/ja not_active Expired - Fee Related
- 2003-06-16 MY MYPI20032245A patent/MY135548A/en unknown
- 2003-06-20 AR AR20030102209A patent/AR040444A1/es not_active Application Discontinuation
-
2005
- 2005-01-20 ZA ZA2005/00585A patent/ZA200500585B/en unknown
- 2005-12-12 HK HK05111395A patent/HK1079430A1/xx not_active IP Right Cessation
-
2006
- 2006-10-16 CY CY20061101478T patent/CY1105706T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN100368013C (zh) | 2008-02-13 |
| AR040444A1 (es) | 2005-04-06 |
| RU2322254C2 (ru) | 2008-04-20 |
| ZA200500585B (en) | 2005-11-30 |
| MXPA04012426A (es) | 2005-04-19 |
| DK1515740T3 (da) | 2006-12-11 |
| CY1105706T1 (el) | 2010-12-22 |
| PT1515740E (pt) | 2007-01-31 |
| US20050239692A1 (en) | 2005-10-27 |
| WO2004000344A1 (de) | 2003-12-31 |
| ES2270042T3 (es) | 2007-04-01 |
| KR20050013612A (ko) | 2005-02-04 |
| JP2005534671A (ja) | 2005-11-17 |
| EP1515740B1 (de) | 2006-08-23 |
| PL372192A1 (en) | 2005-07-11 |
| AU2003240268A1 (en) | 2004-01-06 |
| CA2490735C (en) | 2012-11-20 |
| BR0312157A (pt) | 2005-03-29 |
| CN1662250A (zh) | 2005-08-31 |
| CA2490735A1 (en) | 2003-12-31 |
| DE50304763D1 (de) | 2006-10-05 |
| US7262165B2 (en) | 2007-08-28 |
| PL205972B1 (pl) | 2010-06-30 |
| KR101024511B1 (ko) | 2011-03-31 |
| RU2005101746A (ru) | 2005-08-27 |
| DE10228049A1 (de) | 2004-01-15 |
| JP5052750B2 (ja) | 2012-10-17 |
| MY135548A (en) | 2008-05-30 |
| AU2003240268B2 (en) | 2008-10-23 |
| ATE337013T1 (de) | 2006-09-15 |
| EP1515740A1 (de) | 2005-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1079430A1 (en) | Liquid preparation comprising oligopeptides and etherified cyclodextrin | |
| AU2003299778A8 (en) | Antibodies against gpr64 and uses thereof | |
| EP1661818A4 (en) | DISCHARGE BODY, DISCHARGE CONTAINER COMPRISING THE DISCHARGE BODY AND INSTILLATION CONTAINER | |
| TWI348890B (en) | Mixtures comprising strobilurins and ethylene modulators | |
| PT1592426E (pt) | 2-cianopirrolopirimidinas e seus usos farmacêuticos | |
| HK1088837A1 (en) | Clk-peptide and slk-peptide | |
| EP1616873A4 (en) | LIPID REGULATING MEDIUM AND ITS USE | |
| EP1589033A4 (en) | ANTIBODY AND ITS USE | |
| EP1288221A4 (en) | oligopeptides | |
| AU2001262689A1 (en) | Oligopeptides | |
| GB0309064D0 (en) | Modified peptides and their uses | |
| IL161387A0 (en) | Rankl mimics and uses thereof | |
| HK1209049A1 (en) | Survivin-derived peptides and use thereof | |
| GB2400659B (en) | Assay methods and materials | |
| AU2002354567A8 (en) | Bcr-Abl oligomerization domain polypeptides and uses therefor | |
| AU2003244927A1 (en) | Forestalling long time-outs in processes | |
| GB0107628D0 (en) | Substances | |
| GB0114533D0 (en) | Substances | |
| SI1515740T1 (sl) | Tekoci pripravek, ki vsebuje oligopeptide in zaetreni ciklodekstrin | |
| PL1694845T3 (pl) | Przeciwciała przeciwko rakowi i ich zastosowania | |
| GB0115071D0 (en) | Substances | |
| GB0017184D0 (en) | Container assembly and container unit | |
| EP1699809A4 (en) | PEPTIDE FROM AMNIOTIC LIQUID AND USES THEREOF | |
| EP1627888A4 (en) | ANTIBODY AND ITS USE | |
| GB0116185D0 (en) | Substances |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20140519 |